Drugs / MK6186
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01152255 | Oct 2010 → Jun 2011 | HIV infectious disease | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-6186 | “In 2 sequential panels, 18 participants received MK-6186 (40 mg [Panel A] or 150 mg [Panel B]) or matching placebo once daily for 7 days.” PMID 39291814 ↗ Oct 2024 |
| Action | Inhibit | “MK-6186, an HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor” PMID 39291814 ↗ Oct 2024 |
| Modality | Small molecule | — CHEMBL1939499 ↗ |
| Route | Oral | “40 mg oral dose once daily for 7 days” NCT01152255 ↗ |